The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Karaman A, Omeroglu M, Emet M, Kerget B, Subasi ID, Alper F

Lenalidomide Induced Late-Onset Acute Respiratory Distress Syndrome.

The Eurasian journal of medicine 2016 Oct;48;228-229 — 2016 Oct — 228-229

Amraoui K, Belhadj K, Maître B, Jannière-Nartey C, Dupuis J

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.

European respiratory review : an official journal of the European Respiratory Society 2013 Mar 01;22;93-5 — 2013 Mar 01 — 93-5

Kunimasa K, Ueda T, Arita M, Maeda T, Hotta M, Ishida T

Drug-induced interstitial pneumonitis due to low-dose lenalidomide.

Internal medicine (Tokyo, Japan) 2012;51;1081-5 — 2012 — 1081-5

Iino M

Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.

International journal of hematology 2012 Feb;95;223-4 — 2012 Feb — 223-4

Zagouri F, Roussou M, Kastritis E, Koureas A, Tsokou E, Migkou M, Gavriatopoulou M, Nikitas N, Gkotzamanidou M, Terpos E, Dimopoulos MA

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.

American journal of hematology 2011 Oct;86;882-4 — 2011 Oct — 882-4

Coates S, Barker A, Spurgeon S

Reversible pulmonary toxicity due to lenalidomide.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2012 Jun;18;284-6 — 2012 Jun — 284-6

Lerch E, Györik S, Feilchenfeldt J, Mazzucchelli L, Quadri F

A case of lenalidomide-induced hypersensitivity pneumonitis.

Onkologie 2010;33;249-52 — 2010 — 249-52

Chen Y, Kiatsimkul P, Nugent K, Raj R

Lenalidomide-induced interstitial lung disease.

Pharmacotherapy 2010 Mar;30;325 — 2010 Mar — 325

Thornburg A, Abonour R, Smith P, Knox K, Twigg HL

Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.

Chest 2007 May;131;1572-4 — 2007 May — 1572-4

Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Blood 2005 Dec 15;106;4050-3 — 2005 Dec 15 — 4050-3